Skip to content

Omeros OMER Restricted Cash

Restricted Cash at other companies

Immunome logo
ImmunomeIMNM
$210K+110%
Annexon logo
AnnexonANNX
$1.03M0.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M0.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$5.81M+0.1%
Alumis Inc. logo
Alumis Inc.ALMS
$86K-92.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
$816K0.0%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's restricted cash?
Omeros (OMER) reported restricted cash of $1.05M in Q1 2026.
How has Omeros's restricted cash changed year-over-year?
Omeros's restricted cash decreased by 0.0% year-over-year, from $1.05M to $1.05M.
What is the long-term trend for Omeros's restricted cash?
Over 5 years (2020 to 2025), Omeros's restricted cash has grown at a -0.0% compound annual growth rate (CAGR), from $1.06M to $1.05M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.